Oncocyte Corporation announced the peer-reviewed publication of the results of a study applying DetermaIO™ to samples collected from the randomized Phase II AtezoTRIBE clinical trial in metastatic colorectal cancer (mCRC). The results were published in Clinical Cancer Research and showed the utility of DetermaIO in potentially identifying more responders to ICI therapy than current standard of care biomarkers. Highlights of the peer-reviewed publication include: In the overall population (n=122), DetermaIO positive patients achieved better outcomes in terms of progression-free survival from the addition of atezolizumab among mCRC patients than DetermaIO negative patients, regardless of MMR status.

A similar trend was observed in the pMMR population (n=110) that does not currently qualify for ICI therapy in mCRC. In the pMMR group treated with ICI addition to chemo (N=69), patients that had a very high DetermaIO had a significantly improved progression-free survival (HR=0.19 95% CI: 0.09 - 0.40). Overlap between DetermaIO positive, dMMR, and TMB is limited, demonstrating DetermaIO identifies a unique subset of patients not identified by these biomarkers.